Norway· NO-ID_88DECFCD-FC97-4199-B7AF-BEE81CD80F2D
Nerlynx
A neratinib product containing neratinib, registered in Norway by Pierre Fabre Medicament. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Neratinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EH02 (neratinib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 8 of them publish a price we can compare per daily dose
Neratinib · ATC L01EH02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Neratinib
- Manufacturer
- Pierre Fabre Medicament
- Country
- Norway (NO)
- ATC code
- L01EH02
- ATC class
- Neratinib
- Defined daily dose
- 0.24 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- September 25, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_88DECFCD-FC97-4199-B7AF-BEE81CD80F2D
- no_varenummer181310180NOK 63272
- gtin3573994004851
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
226 interactions on record for neratinib.
Graded by severity as the source publishes them — 97 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Neratinib · interactions on record
226 records
- 97 severe
- 123 moderate
- 6 minor
Most severe, free to view
- ClotrimazoleA01AB18severe
- CimetidineA02BA01severe
- RanitidineA02BA02severe
- FamotidineA02BA03severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Neratinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumNerlynx 40 mgPierre Fabre Médicament
- SwitzerlandNerlynx 40 mg, FilmtablettenPierre Fabre Pharma SA
- CzechiaNERLYNXPIERRE FABRE MEDICAMENT, Lavaur
- SpainNERLYNX 40 MG COMPRIMIDOS RECUBIERTOS CON PELICULAPierre Fabre Medicament
- FinlandNerlynxPierre Fabre Medicament
- IrelandNerlynx 40 mg Film-coated tabletPierre Fabre Medicament
- IcelandNerlynxPierre Fabre Medicament
- NetherlandsNerlynx 40 mg, filmomhulde tablettenPierre Fabre Medicament
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Nerlynx
- Liechtenstein · Nerlynx
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f45c7c24-ce50-4d0c-bcae-1491e21bb80f GET /v1/drugs/f45c7c24-ce50-4d0c-bcae-1491e21bb80f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Neratinib",
"merkevare_id": "ID_88DECFCD-FC97-4199-B7AF-BEE81CD80F2D",
"name_form_strength": "Nerlynx tab 40 mg",
"prescription_group": "C"
}See everything about neratinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.